Gastroesophageal Junction Adenocarcinoma Clinical Trials in Orlando, Florida

5 studies are recruiting for gastroesophageal junction adenocarcinoma in Orlando, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

   This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line therapy in adults with gastric or gastroesophageal junction (GEJ) that is locally advanced and cannot …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Orlando Health Cancer Institute Downtown Orlando, Orlando, Florida

   Locations

   95 in total

   Run by

   BeOne Medicines

   See if you can join NCT07043400 on ClinicalTrials.gov

2. A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

   This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced o…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Orlando, Florida

   Locations

   302 in total

   Run by

   AstraZeneca

   See if you can join NCT06764875 on ClinicalTrials.gov

3. Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

   The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GE…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Orlando, Florida

   Locations

   311 in total

   Run by

   AstraZeneca

   See if you can join NCT07431281 on ClinicalTrials.gov

4. A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

   This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Florida Cancer Specialists, Orlando, Florida

   Locations

   48 in total

   Run by

   Seagen, a wholly owned subsidiary of Pfizer

   See if you can join NCT06131840 on ClinicalTrials.gov

5. A Study of Sigvotatug Vedotin in Advanced Solid Tumors

   This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Florida Cancer Specialists, Orlando, Florida

   Locations

   158 in total

   Run by

   Seagen, a wholly owned subsidiary of Pfizer

   See if you can join NCT04389632 on ClinicalTrials.gov